{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:39:57Z","timestamp":1793824797527,"version":"4.6.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1038\/s41582-020-00416-1","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T06:05:02Z","timestamp":1604901902000},"page":"23-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Genetic testing in dementia \u2014 utility and clinical strategies"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-4938","authenticated-orcid":false,"given":"Carolin A. M.","family":"Koriath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Rohrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2059-024X","authenticated-orcid":false,"given":"Jonathan M.","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-7777","authenticated-orcid":false,"given":"Henry","family":"Houlden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick C.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2716-2045","authenticated-orcid":false,"given":"Sarah J.","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4326-1468","authenticated-orcid":false,"given":"Simon","family":"Mead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"416_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","volume":"10","author":"SJ Tabrizi","year":"2011","unstructured":"Tabrizi, S. J. et al. Biological and clinical changes in premanifest and early stage Huntington\u2019s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 10, 31\u201342 (2011).","journal-title":"Lancet Neurol."},{"key":"416_CR2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 280\u2013292 (2011).","journal-title":"Alzheimers Dement."},{"key":"416_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neurobiolaging.2015.10.013","volume":"39","author":"KA Andrews","year":"2016","unstructured":"Andrews, K. A. et al. Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. Neurobiol. Aging 39, 99\u2013107 (2016).","journal-title":"Neurobiol. Aging"},{"key":"416_CR4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J., Ghosh, R. & Leavitt, B. R. Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron 101, 801\u2013819 (2019).","journal-title":"Neuron"},{"key":"416_CR5","doi-asserted-by":"crossref","first-page":"P262","DOI":"10.1016\/j.jalz.2015.07.338","volume":"11","author":"H Liu-Seifert","year":"2015","unstructured":"Liu-Seifert, H., Aisen, P. S., Andersen, S. W., Holdridge, K. C., Siemers, E. R. Delayed-start analyses of up to 3.5 years in the phase 3 solanezumab expedition program in mild Alzheimer\u2019s disease. Alzheimers Dement. 11, P262\u2013P263 (2015).","journal-title":"Alzheimers Dement."},{"key":"416_CR6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou, Y. et al. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol. 15, 565\u2013581 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"416_CR7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","volume":"51","author":"IE Jansen","year":"2019","unstructured":"Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer\u2019s disease risk. Nat. Genet. 51, 404\u2013413 (2019).","journal-title":"Nat. Genet."},{"key":"416_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","volume":"13","author":"RJ Bateman","year":"2017","unstructured":"Bateman, R. J. et al. The DIAN-TU Next Generation Alzheimer\u2019s prevention trial: Adaptive design and disease progression model. Alzheimers Dement. 13, 8\u201319 (2017).","journal-title":"Alzheimers Dement."},{"key":"416_CR9","unstructured":"Alector. Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia GlobalNewsWire https:\/\/www.globenewswire.com\/news-release\/2019\/09\/09\/1912694\/0\/en\/Alector-Initiates-Phase-2-Trial-of-AL001-in-Patients-with-Frontotemporal-Dementia.html (2019)."},{"key":"416_CR10","doi-asserted-by":"crossref","DOI":"10.4081\/ni.2011.e1","volume":"3","author":"ER Atkins","year":"2011","unstructured":"Atkins, E. R. & Panegyres, P. K. The clinical utility of gene testing for Alzheimer\u2019s disease. Neurol. Int. 3, e1 (2011).","journal-title":"Neurol. Int."},{"key":"416_CR11","first-page":"398","volume":"97","author":"N Falk","year":"2018","unstructured":"Falk, N., Cole, A. & Meredith, T. J. Evaluation of suspected dementia. Am. Fam. Physician 97, 398\u2013405 (2018).","journal-title":"Am. Fam. Physician"},{"key":"416_CR12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCRESAHA.116.308426","volume":"120","author":"M Dichgans","year":"2017","unstructured":"Dichgans, M. & Leys, D. Vascular cognitive impairment. Circ. Res. 120, 573\u2013591 (2017).","journal-title":"Circ. Res."},{"key":"416_CR13","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.220","volume":"6","author":"MJ Keogh","year":"2016","unstructured":"Keogh, M. J. et al. Exome sequencing in dementia with Lewy bodies. Transl Psychiatry 6, e728 (2016).","journal-title":"Transl Psychiatry"},{"key":"416_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/ageing\/afu143","volume":"44","author":"J Ngo","year":"2015","unstructured":"Ngo, J. & Holroyd-Leduc, J. M. Systematic review of recent dementia practice guidelines. Age Ageing 44, 25\u201333 (2015).","journal-title":"Age Ageing"},{"key":"416_CR15","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp.2009.199653","volume":"82","author":"JC Stevens","year":"2011","unstructured":"Stevens, J. C. et al. Familial Alzheimer\u2019s disease and inherited prion disease in the UK are poorly ascertained. J. Neurol. Neurosurg. Psychiatry 82, 1054\u20131057 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"416_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/B978-0-444-63233-3.00002-6","volume":"147","author":"BL Fogel","year":"2018","unstructured":"Fogel, B. L. Genetic and genomic testing for neurologic disease in clinical practice. Handb. Clin. Neurol. 147, 11\u201322 (2018).","journal-title":"Handb. Clin. Neurol."},{"key":"416_CR17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.neurobiolaging.2013.07.017","volume":"35","author":"J Beck","year":"2014","unstructured":"Beck, J. et al. Validation of next-generation sequencing technologies in genetic diagnosis of dementia. Neurobiol. Aging 35, 261\u2013265 (2014).","journal-title":"Neurobiol. Aging"},{"key":"416_CR18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/mp.2013.24","volume":"18","author":"K Nho","year":"2013","unstructured":"Nho, K. et al. Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Mol. Psychiatry 18, 781\u2013787 (2013).","journal-title":"Mol. Psychiatry"},{"key":"416_CR19","doi-asserted-by":"crossref","first-page":"19096","DOI":"10.1073\/pnas.0910672106","volume":"106","author":"M Choi","year":"2009","unstructured":"Choi, M. et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc. Natl Acad. Sci. USA. 106, 19096\u201319101 (2009).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"416_CR20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/gim.2017.102","volume":"20","author":"C Blauwendraat","year":"2018","unstructured":"Blauwendraat, C. et al. The wide genetic landscape of clinical frontotemporal dementia: systematic combined sequencing of 121 consecutive subjects. Genet. Med. 20, 240\u2013249 (2018).","journal-title":"Genet. Med."},{"key":"416_CR21","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa1306555","volume":"369","author":"Y Yang","year":"2013","unstructured":"Yang, Y. et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N. Engl. J. Med. 369, 1502\u20131511 (2013).","journal-title":"N. Engl. J. Med."},{"key":"416_CR22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/gim.2016.190","volume":"19","author":"SS Kalia","year":"2017","unstructured":"Kalia, S. S. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet. Med. 19, 249\u2013255 (2017).","journal-title":"Genet. Med."},{"key":"416_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0224-0.","author":"C Koriath","year":"2018","unstructured":"Koriath, C. et al. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. Mol. Psychiatry https:\/\/doi.org\/10.1038\/s41380-018-0224-0. (2018). This paper provides evidence-based recommendations on which patients with dementia to test with which test as well as calculations on how frequent a variant can be in the population for a high likelihood that it is a fully penetrant variant that causes early-onset dementia.","journal-title":"Mol. Psychiatry"},{"key":"416_CR24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245\u2013256 (2011).","journal-title":"Neuron"},{"key":"416_CR25","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1093\/hmg\/ddv246","volume":"24","author":"T Sposito","year":"2015","unstructured":"Sposito, T. et al. Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10+16 splice-site mutation in MAPT. Hum. Mol. Genet. 24, 5260\u20135269 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"416_CR26","doi-asserted-by":"publisher","unstructured":"Bj\u00f6rn Na, P.S., Sigurgeirsson B., Lundeberg J., Gr\u00e9en H. & Sahl\u00e9n P. Comparison of variant calls from whole genome and whole exome sequencing data using matched samples. J. Next Gene. Sequencing Appl. 5, 1 https:\/\/doi.org\/10.4172\/2469-9853.1000154 (2018).","DOI":"10.4172\/2469-9853.1000154"},{"key":"416_CR27","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1073\/pnas.1418631112","volume":"112","author":"A Belkadi","year":"2015","unstructured":"Belkadi, A. et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc. Natl Acad. Sci. USA 112, 5473\u20135478 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"416_CR28","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaneurol.2014.1944","volume":"71","author":"BL Fogel","year":"2014","unstructured":"Fogel, B. L. et al. Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia. JAMA Neurol. 71, 1237\u20131246 (2014).","journal-title":"JAMA Neurol."},{"key":"416_CR29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.14336\/AD.2018.0208","volume":"9","author":"Y Xu","year":"2018","unstructured":"Xu, Y. et al. The whole exome sequencing clarifies the genotype- phenotype correlations in patients with early-onset dementia. Aging Dis. 9, 696\u2013705 (2018).","journal-title":"Aging Dis."},{"key":"416_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10048-017-0532-6","volume":"19","author":"D Galatolo","year":"2018","unstructured":"Galatolo, D., Tessa, A., Filla, A. & Santorelli, F. M. Clinical application of next generation sequencing in hereditary spinocerebellar ataxia: increasing the diagnostic yield and broadening the ataxia-spasticity spectrum. A retrospective analysis. Neurogenetics 19, 1\u20138 (2018).","journal-title":"Neurogenetics"},{"key":"416_CR31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/JAD-160469","volume":"55","author":"D Cuccaro","year":"2017","unstructured":"Cuccaro, D., De Marco, E. V., Cittadella, R. & Cavallaro, S. Copy number variants in Alzheimer\u2019s disease. J. Alzheimers Dis. 55, 37\u201352 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"416_CR32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13024-018-0274-4","volume":"13","author":"MTW Ebbert","year":"2018","unstructured":"Ebbert, M. T. W. et al. Long-read sequencing across the C9orf72 \u2018GGGGCC\u2019 repeat expansion: implications for clinical use and genetic discovery efforts in human disease. Mol. Neurodegener. 13, 46 (2018).","journal-title":"Mol. Neurodegener."},{"key":"416_CR33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1055\/s-0039-1688446","volume":"45","author":"KR Kumar","year":"2019","unstructured":"Kumar, K. R., Cowley, M. J. & Davis, R. L. Next-generation sequencing and emerging technologies. Semin. Thromb. Hemost. 45, 661\u2013673 (2019).","journal-title":"Semin. Thromb. Hemost."},{"key":"416_CR34","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-017-1705-x","volume":"18","author":"F Zare","year":"2017","unstructured":"Zare, F., Dow, M., Monteleone, N., Hosny, A. & Nabavi, S. An evaluation of copy number variation detection tools for cancer using whole exome sequencing data. BMC Bioinformatics 18, 286 (2017).","journal-title":"BMC Bioinformatics"},{"key":"416_CR35","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1101\/gr.225672.117","volume":"27","author":"E Dolzhenko","year":"2017","unstructured":"Dolzhenko, E. et al. Detection of long repeat expansions from PCR-free whole-genome sequence data. Genome Res. 27, 1895\u20131903 (2017). This study demonstrated how PCR-free WGS data can be analysed for trinucleotide repeat expansions.","journal-title":"Genome Res."},{"key":"416_CR36","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz501","volume":"47","author":"N Mousavi","year":"2019","unstructured":"Mousavi, N., Shleizer-Burko, S., Yanicky, R. & Gymrek, M. Profiling the genome-wide landscape of tandem repeat expansions. Nucleic Acids Res. 47, e90 (2019).","journal-title":"Nucleic Acids Res."},{"key":"416_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7659-1_1","volume":"1741","author":"KO Wrzeszczynski","year":"2018","unstructured":"Wrzeszczynski, K. O. et al. Whole genome sequencing-based discovery of structural variants in glioblastoma. Methods Mol. Biol. 1741, 1\u201329 (2018).","journal-title":"Methods Mol. Biol."},{"key":"416_CR38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3389\/fgene.2019.00426","volume":"10","author":"T Mantere","year":"2019","unstructured":"Mantere, T., Kersten, S. & Hoischen, A. Long-read sequencing emerging in medical genetics. Front. Genet. 10, 426 (2019).","journal-title":"Front. Genet."},{"key":"416_CR39","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2164-13-375","volume":"13","author":"MO Carneiro","year":"2012","unstructured":"Carneiro, M. O. et al. Pacific biosciences sequencing technology for genotyping and variation discovery in human data. BMC Genomics 13, 375 (2012).","journal-title":"BMC Genomics"},{"key":"416_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bdq.2015.02.001","volume":"3","author":"T Laver","year":"2015","unstructured":"Laver, T. et al. Assessing the performance of the Oxford Nanopore Technologies MinION. Biomol. Detect. Quantif. 3, 1\u20138 (2015).","journal-title":"Biomol. Detect. Quantif."},{"key":"416_CR41","unstructured":"NHS England. National Genomic Test Directory. NHS https:\/\/www.england.nhs.uk\/publication\/national-genomic-test-directories\/ (2018)."},{"key":"416_CR42","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/jmedgenet-2018-105396","volume":"55","author":"L Mestek-Boukhibar","year":"2018","unstructured":"Mestek-Boukhibar, L. et al. Rapid Paediatric Sequencing (RaPS): comprehensive real-life workflow for rapid diagnosis of critically ill children. J. Med. Genet. 55, 721\u2013728 (2018).","journal-title":"J. Med. Genet."},{"key":"416_CR43","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/gim.2015.148","volume":"18","author":"K Retterer","year":"2016","unstructured":"Retterer, K. et al. Clinical application of whole-exome sequencing across clinical indications. Genet. Med. 18, 696\u2013704 (2016).","journal-title":"Genet. Med."},{"key":"416_CR44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285\u2013291 (2016).","journal-title":"Nature"},{"key":"416_CR45","doi-asserted-by":"crossref","first-page":"322ra9","DOI":"10.1126\/scitranslmed.aad5169","volume":"8","author":"EV Minikel","year":"2016","unstructured":"Minikel, E. V. et al. Quantifying prion disease penetrance using large population control cohorts. Sci. Transl Med. 8, 322ra9 (2016). In this study, elegant maths was used to demonstrate the importance of harnessing genetic variant population databases to assess variant pathogenicity because, in rare diseases such as prion disease, some variants that are reported as pathogenic are too frequent in the population to be fully penetrant causal mutations.","journal-title":"Sci. Transl Med."},{"key":"416_CR46","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/WNL.0b013e31820a0d13","volume":"76","author":"JS Goldman","year":"2011","unstructured":"Goldman, J. S. et al. An algorithm for genetic testing of frontotemporal lobar degeneration. Neurology 76, 475\u2013483 (2011).","journal-title":"Neurology"},{"key":"416_CR47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.psc.2015.01.008","volume":"38","author":"JS Goldman","year":"2015","unstructured":"Goldman, J. S. Genetic testing and counseling in the diagnosis and management of young-onset dementias. Psychiatr. Clin. North Am. 38, 295\u2013308 (2015).","journal-title":"Psychiatr. Clin. North Am."},{"key":"416_CR48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/B978-0-444-64076-5.00027-2","volume":"148","author":"J Deleon","year":"2018","unstructured":"Deleon, J. & Miller, B. L. Frontotemporal dementia. Handb. Clin. Neurol. 148, 409\u2013430 (2018).","journal-title":"Handb. Clin. Neurol."},{"key":"416_CR49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-444-63233-3.00001-4","volume":"147","author":"TD Bird","year":"2018","unstructured":"Bird, T. D. & Smith, C. O. Clinical approach to the patient with neurogenetic disease. Handb. Clin. Neurol. 147, 3\u20139 (2018).","journal-title":"Handb. Clin. Neurol."},{"key":"416_CR50","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/nan.12100","volume":"40","author":"T Lashley","year":"2014","unstructured":"Lashley, T. et al. A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia. Neuropathol. Appl. Neurobiol. 40, 502\u2013513 (2014).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"416_CR51","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jns.2014.03.030","volume":"341","author":"A Mignarri","year":"2014","unstructured":"Mignarri, A. et al. Double trouble? Progranulin mutation and C9ORF72 repeat expansion in a case of primary non-fluent aphasia. J. Neurol. Sci. 341, 176\u2013178 (2014).","journal-title":"J. Neurol. Sci."},{"key":"416_CR52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-141794","volume":"44","author":"S Testi","year":"2015","unstructured":"Testi, S., Tamburin, S., Zanette, G. & Fabrizi, G. M. Co-occurrence of the C9ORF72 expansion and a novel GRN mutation in a family with alternative expression of frontotemporal dementia and amyotrophic lateral sclerosis. J. Alzheimers Dis. 44, 49\u201356 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"416_CR53","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.3390\/ijms20163903","volume":"20","author":"M Ciani","year":"2019","unstructured":"Ciani, M. et al. The missing heritability of sporadic frontotemporal dementia: new insights from rare variants in neurodegenerative candidate genes. Int. J. Mol. Sci. 20, 3903 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"416_CR54","doi-asserted-by":"crossref","first-page":"11878","DOI":"10.1073\/pnas.1815601116","volume":"116","author":"S Papadimitriou","year":"2019","unstructured":"Papadimitriou, S. et al. Predicting disease-causing variant combinations. Proc. Natl Acad. Sci. USA 116, 11878\u201311887 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"416_CR55","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(10)70159-9","volume":"9","author":"MN Rossor","year":"2010","unstructured":"Rossor, M. N., Fox, N. C., Mummery, C. J., Schott, J. M. & Warren, J. D. The diagnosis of young-onset dementia. Lancet Neurol. 9, 793\u2013806 (2010).","journal-title":"Lancet Neurol."},{"key":"416_CR56","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fneur.2015.00142","volume":"6","author":"SE Schindler","year":"2015","unstructured":"Schindler, S. E. & Fagan, A. M. Autosomal dominant Alzheimer disease: a unique resource to study CSF biomarker changes in preclinical AD. Front. Neurol. 6, 142 (2015).","journal-title":"Front. Neurol."},{"key":"416_CR57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1212\/WNL.0000000000000596","volume":"83","author":"DC Ryman","year":"2014","unstructured":"Ryman, D. C. et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83, 253\u2013260 (2014).","journal-title":"Neurology"},{"key":"416_CR58","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/brain\/120.3.491","volume":"120","author":"NC Fox","year":"1997","unstructured":"Fox, N. C. et al. Clinicopathological features of familial Alzheimer\u2019s disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain 120, 491\u2013501 (1997).","journal-title":"Brain"},{"key":"416_CR59","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","volume":"25","author":"JF Arboleda-Velasquez","year":"2019","unstructured":"Arboleda-Velasquez, J. F. et al. Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25, 1680\u20131683 (2019).","journal-title":"Nat. Med."},{"key":"416_CR60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13195-018-0374-y","volume":"10","author":"S Thordardottir","year":"2018","unstructured":"Thordardottir, S. et al. Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. Alzheimers Res. Ther. 10, 45 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"416_CR61","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0140-6736(96)90715-1","volume":"347","author":"MN Rossor","year":"1996","unstructured":"Rossor, M. N., Fox, N. C., Beck, J., Campbell, T. C. & Collinge, J. Incomplete penetrance of familial Alzheimer\u2019s disease in a pedigree with a novel presenilin-1 gene mutation. Lancet 347, 1560 (1996).","journal-title":"Lancet"},{"key":"416_CR62","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/13554794.2013.826697","volume":"20","author":"Y Liang","year":"2014","unstructured":"Liang, Y. et al. A cognitive chameleon: lessons from a novel MAPT mutation case. Neurocase 20, 684\u2013694 (2014).","journal-title":"Neurocase"},{"key":"416_CR63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev-genet-120213-092352","volume":"53","author":"S Mead","year":"2019","unstructured":"Mead, S., Lloyd, S. & Collinge, J. Genetic factors in mammalian prion diseases. Annu. Rev. Genet. 53, 117\u2013147 (2019).","journal-title":"Annu. Rev. Genet."},{"key":"416_CR64","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.neurobiolaging.2008.01.005","volume":"30","author":"L Bernardi","year":"2009","unstructured":"Bernardi, L. et al. Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. Neurobiol. Aging 30, 1825\u20131833 (2009).","journal-title":"Neurobiol. Aging"},{"key":"416_CR65","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/alz.12011","volume":"16","author":"EM Ramos","year":"2020","unstructured":"Ramos, E. M. et al. Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. Alzheimers Dement. 16, 118\u2013130 (2020).","journal-title":"Alzheimers Dement."},{"key":"416_CR66","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S1474-4422(16)30193-4","volume":"15","author":"NS Ryan","year":"2016","unstructured":"Ryan, N. S. et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer\u2019s disease: a case series. Lancet Neurol. 15, 1326\u20131335 (2016). An excellent exploration of the genetic causes of early-onset AD.","journal-title":"Lancet Neurol."},{"key":"416_CR67","doi-asserted-by":"crossref","first-page":"238.e1","DOI":"10.1016\/j.neurobiolaging.2019.05.014","volume":"84","author":"G Guven","year":"2019","unstructured":"Guven, G. et al. A patient with early-onset Alzheimer\u2019s disease with a novel PSEN1 p.Leu424Pro mutation. Neurobiol. Aging 84, 238.e1\u2013238.e4 (2019).","journal-title":"Neurobiol. Aging"},{"key":"416_CR68","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1212\/WNL.0000000000000335","volume":"82","author":"MM Carrasquillo","year":"2014","unstructured":"Carrasquillo, M. M. et al. Late-onset Alzheimer disease genetic variants in posterior cortical atrophy and posterior AD. Neurology 82, 1455\u20131462 (2014).","journal-title":"Neurology"},{"key":"416_CR69","volume":"8","author":"EJ Sitek","year":"2013","unstructured":"Sitek, E. J. et al. A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene. PLoS ONE 8, e61074 (2013).","journal-title":"PLoS ONE"},{"key":"416_CR70","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.neubiorev.2014.02.010","volume":"42","author":"M Canevelli","year":"2014","unstructured":"Canevelli, M. et al. Familial Alzheimer\u2019s disease sustained by presenilin 2 mutations: systematic review of literature and genotype-phenotype correlation. Neurosci. Biobehav. Rev. 42, 170\u2013179 (2014).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"416_CR71","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3233\/JAD-2012-120172","volume":"30","author":"D Wallon","year":"2012","unstructured":"Wallon, D. et al. The French series of autosomal dominant early onset Alzheimer\u2019s disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J. Alzheimers Dis. 30, 847\u2013856 (2012).","journal-title":"J. Alzheimers Dis."},{"key":"416_CR72","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.neurobiolaging.2015.08.026","volume":"36","author":"NS Ryan","year":"2015","unstructured":"Ryan, N. S. et al. Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer\u2019s disease. Neurobiol. Aging 36, 3140\u20133151 (2015).","journal-title":"Neurobiol. Aging"},{"key":"416_CR73","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jfma.2015.08.004","volume":"115","author":"YF Shea","year":"2016","unstructured":"Shea, Y. F. et al. A systematic review of familial Alzheimer\u2019s disease: differences in presentation of clinical features among three mutated genes and potential ethnic differences. J. Formos. Med. Assoc. 115, 67\u201375 (2016).","journal-title":"J. Formos. Med. Assoc."},{"key":"416_CR74","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/brain\/awz050","volume":"142","author":"J Voglein","year":"2019","unstructured":"Voglein, J. et al. Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer\u2019s disease. Brain 142, 1429\u20131440 (2019).","journal-title":"Brain"},{"key":"416_CR75","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/S0002-9440(10)64688-3","volume":"158","author":"DM Mann","year":"2001","unstructured":"Mann, D. M., Pickering-Brown, S. M., Takeuchi, A. & Iwatsubo, T. Members of the Familial Alzheimer\u2019s Disease Pathology Study Group. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer\u2019s disease. Am. J. Pathol. 158, 2165\u20132175 (2001).","journal-title":"Am. J. Pathol."},{"key":"416_CR76","doi-asserted-by":"crossref","first-page":"426.e13","DOI":"10.1016\/j.neurobiolaging.2010.10.010","volume":"33","author":"D McNaughton","year":"2012","unstructured":"McNaughton, D. et al. Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiol. Aging 33, 426.e13\u201321 (2012).","journal-title":"Neurobiol. Aging"},{"key":"416_CR77","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2217\/bmm.09.92","volume":"4","author":"NS Ryan","year":"2010","unstructured":"Ryan, N. S. & Rossor, M. N. Correlating familial Alzheimer\u2019s disease gene mutations with clinical phenotype. Biomark Med. 4, 99\u2013112 (2010).","journal-title":"Biomark Med."},{"key":"416_CR78","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.0000000000003048","volume":"87","author":"A Zarea","year":"2016","unstructured":"Zarea, A. et al. Seizures in dominantly inherited Alzheimer disease. Neurology 87, 912\u2013919 (2016).","journal-title":"Neurology"},{"key":"416_CR79","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","volume":"41","author":"D Harold","year":"2009","unstructured":"Harold, D. et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease. Nat. Genet. 41, 1088\u20131093 (2009).","journal-title":"Nat. Genet."},{"key":"416_CR80","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat. Genet. 45, 1452\u20131458 (2013).","journal-title":"Nat. Genet."},{"key":"416_CR81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro, R. et al. TREM2 variants in Alzheimer\u2019s disease. N. Engl. J. Med. 368, 117\u2013127 (2013).","journal-title":"N. Engl. J. Med."},{"key":"416_CR82","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ng.803","volume":"43","author":"P Hollingworth","year":"2011","unstructured":"Hollingworth, P. et al. Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer\u2019s disease. Nat. Genet. 43, 429\u2013435 (2011).","journal-title":"Nat. Genet."},{"key":"416_CR83","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1093\/brain\/awv268","volume":"138","author":"V Escott-Price","year":"2015","unstructured":"Escott-Price, V. et al. Common polygenic variation enhances risk prediction for Alzheimer\u2019s disease. Brain 138, 3673\u20133684 (2015).","journal-title":"Brain"},{"key":"416_CR84","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/alzrt204","volume":"5","author":"AB Wolf","year":"2013","unstructured":"Wolf, A. B. et al. Apolipoprotein E as a beta-amyloid-independent factor in Alzheimer\u2019s disease. Alzheimers Res. Ther. 5, 38 (2013).","journal-title":"Alzheimers Res. Ther."},{"key":"416_CR85","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","volume":"101","author":"ME Belloy","year":"2019","unstructured":"Belloy, M. E., Napolioni, V. & Greicius, M. D. A quarter century of APOE and Alzheimer\u2019s disease: progress to date and the path forward. Neuron 101, 820\u2013838 (2019).","journal-title":"Neuron"},{"key":"416_CR86","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1007\/s12035-018-1237-z","volume":"56","author":"MS Uddin","year":"2019","unstructured":"Uddin, M. S. et al. APOE and Alzheimer\u2019s disease: evidence mounts that targeting APOE4 may combat Alzheimer\u2019s pathogenesis. Mol. Neurobiol. 56, 2450\u20132465 (2019).","journal-title":"Mol. Neurobiol."},{"key":"416_CR87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng1934","volume":"39","author":"L Bertram","year":"2007","unstructured":"Bertram, L., McQueen, M. B., Mullin, K., Blacker, D. & Tanzi, R. E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39, 17\u201323 (2007).","journal-title":"Nat. Genet."},{"key":"416_CR88","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ana.410370217","volume":"37","author":"G Maestre","year":"1995","unstructured":"Maestre, G. et al. Apolipoprotein E and Alzheimer\u2019s disease: ethnic variation in genotypic risks. Ann. Neurol. 37, 254\u2013259 (1995).","journal-title":"Ann. Neurol."},{"key":"416_CR89","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/jnnp.57.11.1414","volume":"57","author":"J Kawamata","year":"1994","unstructured":"Kawamata, J., Tanaka, S., Shimohama, S., Ueda, K. & Kimura, J. Apolipoprotein E polymorphism in Japanese patients with Alzheimer\u2019s disease or vascular dementia. J. Neurol. Neurosurg. Psychiatry 57, 1414\u20131416 (1994).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"416_CR90","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman, E. M. et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat. Commun. 11, 667 (2020). In this study, neuropathological data were used to demonstrate the relative risk levels bestowed by the different ApoE genotypes.","journal-title":"Nat. Commun."},{"key":"416_CR91","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.trci.2019.09.013","volume":"5","author":"CM Langlois","year":"2019","unstructured":"Langlois, C. M. et al. Alzheimer\u2019s prevention initiative generation program: development of an APOE genetic counseling and disclosure process in the context of clinical trials. Alzheimers Dement. 5, 705\u2013716 (2019).","journal-title":"Alzheimers Dement."},{"key":"416_CR92","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","volume":"86","author":"IT Coyle-Gilchrist","year":"2016","unstructured":"Coyle-Gilchrist, I. T. et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86, 1736\u20131743 (2016).","journal-title":"Neurology"},{"key":"416_CR93","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1212\/WNL.0b013e3181bf997a","volume":"73","author":"JD Rohrer","year":"2009","unstructured":"Rohrer, J. D. et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 73, 1451\u20131456 (2009).","journal-title":"Neurology"},{"key":"416_CR94","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/brain\/awr361","volume":"135","author":"CJ Mahoney","year":"2012","unstructured":"Mahoney, C. J. et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 135, 736\u2013750 (2012).","journal-title":"Brain"},{"key":"416_CR95","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/31508","volume":"393","author":"M Hutton","year":"1998","unstructured":"Hutton, M. et al. Association of missense and 5\u2019-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702\u2013705 (1998).","journal-title":"Nature"},{"key":"416_CR96","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nature05017","volume":"442","author":"M Cruts","year":"2006","unstructured":"Cruts, M. et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920\u2013924 (2006).","journal-title":"Nature"},{"key":"416_CR97","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","volume":"266","author":"CV Greaves","year":"2019","unstructured":"Greaves, C. V. & Rohrer, J. D. An update on genetic frontotemporal dementia. J. Neurol. 266, 2075\u20132086 (2019).","journal-title":"J. Neurol."},{"key":"416_CR98","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00415-020-09738-y","volume":"267","author":"JM Poos","year":"2020","unstructured":"Poos, J. M. et al. Cognitive profiles discriminate between genetic variants of behavioral frontotemporal dementia. J. Neurol. 267, 1603\u20131612 (2020).","journal-title":"J. Neurol."},{"key":"416_CR99","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(19)30394-1","volume":"19","author":"KM Moore","year":"2020","unstructured":"Moore, K. M. et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 19, 145\u2013156 (2020). An exploration of age at onset, disease duration and age at death in genetic frontotemporal dementia; a significant influence of family history was found.","journal-title":"Lancet Neurol."},{"key":"416_CR100","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/01.wnl.0000187068.92184.63","volume":"65","author":"JS Goldman","year":"2005","unstructured":"Goldman, J. S. et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 65, 1817\u20131819 (2005).","journal-title":"Neurology"},{"key":"416_CR101","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1007\/s00415-014-7474-9","volume":"261","author":"K Po","year":"2014","unstructured":"Po, K. et al. Heritability in frontotemporal dementia: more missing pieces? J. Neurol. 261, 2170\u20132177 (2014).","journal-title":"J. Neurol."},{"key":"416_CR102","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaneurol.2013.3956","volume":"70","author":"EM Wood","year":"2013","unstructured":"Wood, E. M. et al. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol. 70, 1411\u20131417 (2013).","journal-title":"JAMA Neurol."},{"key":"416_CR103","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/02687038.2014.911242","volume":"28","author":"JD Rohrer","year":"2014","unstructured":"Rohrer, J. D. The genetics of primary progressive aphasia. Aphasiology 28, 941\u2013947 (2014).","journal-title":"Aphasiology"},{"key":"416_CR104","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/jnnp-2017-315995","volume":"88","author":"MR Turner","year":"2017","unstructured":"Turner, M. R. et al. Genetic screening in sporadic ALS and FTD. J. Neurol. Neurosurg. Psychiatry 88, 1042\u20131044 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"416_CR105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1474-4422(14)70324-2","volume":"14","author":"JD Rohrer","year":"2015","unstructured":"Rohrer, J. D. et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 14, 253\u2013262 (2015).","journal-title":"Lancet Neurol."},{"key":"416_CR106","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04363684 (2020)."},{"key":"416_CR107","unstructured":"US National Library of Medicine.ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03987295 (2020)."},{"key":"416_CR108","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03636204 (2020)."},{"key":"416_CR109","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04220021 (2020)."},{"key":"416_CR110","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","volume":"95","author":"SB Prusiner","year":"1998","unstructured":"S. B. Prusiner. Nobel Lecture: Prions. Proc. Natl Acad. Sci. USA 95, 13363\u201313383 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"416_CR111","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4161\/pri.27260","volume":"7","author":"M Paucar","year":"2013","unstructured":"Paucar, M. et al. Genotype-phenotype analysis in inherited prion disease with eight octapeptide repeat insertional mutation. Prion 7, 501\u2013510 (2013).","journal-title":"Prion"},{"key":"416_CR112","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrneurol.2014.263","volume":"11","author":"S Mead","year":"2015","unstructured":"Mead, S. & Reilly, M. M. A new prion disease: relationship with central and peripheral amyloidoses. Nat. Rev. Neurol. 11, 90\u201397 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"416_CR113","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0140-6736(10)60974-9","volume":"376","author":"M Rawlins","year":"2010","unstructured":"Rawlins, M. Huntington\u2019s disease out of the closet? Lancet 376, 1372\u20131373 (2010).","journal-title":"Lancet"},{"key":"416_CR114","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates, G. P. et al. Huntington disease. Nat. Rev. Dis. Primers 1, 15005 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"416_CR115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-71779-1_1","volume":"1049","author":"R Ghosh","year":"2018","unstructured":"Ghosh, R. & Tabrizi, S. J. Clinical features of Huntington\u2019s disease. Adv. Exp. Med. Biol. 1049, 1\u201328 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"416_CR116","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-444-63233-3.00017-8","volume":"147","author":"R Ghosh","year":"2018","unstructured":"Ghosh, R. & Tabrizi, S. J. Huntington disease. Handb. Clin. Neurol. 147, 255\u2013278 (2018).","journal-title":"Handb. Clin. Neurol."},{"key":"416_CR117","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/306234a0","volume":"306","author":"JF Gusella","year":"1983","unstructured":"Gusella, J. F. et al. A polymorphic DNA marker genetically linked to Huntington\u2019s disease. Nature 306, 234\u2013238 (1983).","journal-title":"Nature"},{"key":"416_CR118","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1399-0004.2012.01900.x","volume":"83","author":"R MacLeod","year":"2013","unstructured":"MacLeod, R. et al. Recommendations for the predictive genetic test in Huntington\u2019s disease. Clin. Genet. 83, 221\u2013231 (2013). The recommended protocol for how to proceed with counselling for predictive testing in genetic diseases.","journal-title":"Clin. Genet."},{"key":"416_CR119","doi-asserted-by":"crossref","unstructured":"[No authors listed] A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell 72, 971\u2013983 (1993).","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"416_CR120","first-page":"16","volume":"59","author":"DC Rubinsztein","year":"1996","unstructured":"Rubinsztein, D. C. et al. Phenotypic characterization of individuals with 30\u201340 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36\u201339 repeats. Am. J. Hum. Genet. 59, 16\u201322 (1996).","journal-title":"Am. J. Hum. Genet."},{"key":"416_CR121","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/ana.24656","volume":"79","author":"C Bettencourt","year":"2016","unstructured":"Bettencourt, C. et al. DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. Ann. Neurol. 79, 983\u2013990 (2016).","journal-title":"Ann. Neurol."},{"key":"416_CR122","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nn.4014","volume":"18","author":"K Becanovic","year":"2015","unstructured":"Becanovic, K. et al. A SNP in the HTT promoter alters NF-\u03baB binding and is a bidirectional genetic modifier of Huntington disease. Nat. Neurosci. 18, 807\u2013816 (2015).","journal-title":"Nat. Neurosci."},{"key":"416_CR123","first-page":"852","volume":"54","author":"SE Andrew","year":"1994","unstructured":"Andrew, S. E. et al. Huntington disease without CAG expansion: phenocopies or errors in assignment? Am. J. Hum. Genet. 54, 852\u2013863 (1994).","journal-title":"Am. J. Hum. Genet."},{"key":"416_CR124","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/WCO.0b013e3282f12074","volume":"20","author":"EJ Wild","year":"2007","unstructured":"Wild, E. J. & Tabrizi, S. J. Huntington\u2019s disease phenocopy syndromes. Curr. Opin. Neurol. 20, 681\u2013687 (2007).","journal-title":"Curr. Opin. Neurol."},{"key":"416_CR125","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1212\/WNL.0000000000000061","volume":"82","author":"DJ Hensman Moss","year":"2014","unstructured":"Hensman Moss, D. J. et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 82, 292\u2013299 (2014).","journal-title":"Neurology"},{"key":"416_CR126","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015). The recommended guidelines on how to classify variants using all available evidence.","journal-title":"Genet. Med."},{"key":"416_CR127","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/pon.1311","volume":"17","author":"J Vos","year":"2008","unstructured":"Vos, J. et al. The counsellees\u2019 view of an unclassified variant in BRCA1\/2: recall, interpretation, and impact on life. Psychooncology 17, 822\u2013830 (2008).","journal-title":"Psychooncology"},{"key":"416_CR128","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.hrthm.2015.07.002","volume":"12","author":"MJ Ackerman","year":"2015","unstructured":"Ackerman, M. J. Genetic purgatory and the cardiac channelopathies: Exposing the variants of uncertain\/unknown significance issue. Heart Rhythm. 12, 2325\u20132331 (2015).","journal-title":"Heart Rhythm."},{"key":"416_CR129","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/humu.22844","volume":"36","author":"N Sobreira","year":"2015","unstructured":"Sobreira, N., Schiettecatte, F., Valle, D. & Hamosh, A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum. Mutat. 36, 928\u2013930 (2015).","journal-title":"Hum. Mutat."},{"key":"416_CR130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3233\/JAD-180599","volume":"67","author":"G Guven","year":"2019","unstructured":"Guven, G. et al. Peripheral GRN mRNA and serum progranulin levels as a potential indicator for both the presence of splice site mutations and individuals at risk for frontotemporal dementia. J. Alzheimers Dis. 67, 159\u2013167 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"416_CR131","volume":"7","author":"LC Cho Y","year":"2017","unstructured":"Cho Y, L. C. et al. Prevalence of rare genetic variations and their implications in NGS-data interpretation. Sci. Rep. 7, 9810 (2017).","journal-title":"Sci. Rep."},{"key":"416_CR132","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.14601","volume":"312","author":"Y Yang","year":"2014","unstructured":"Yang, Y. et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 312, 1870\u20131879 (2014).","journal-title":"JAMA"},{"key":"416_CR133","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ajhg.2016.03.024","volume":"98","author":"LM Amendola","year":"2016","unstructured":"Amendola, L. M. et al. Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the Clinical Sequencing Exploratory Research Consortium. Am. J. Hum. Genet. 98, 1067\u20131076 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"416_CR134","doi-asserted-by":"crossref","first-page":"aaf6814","DOI":"10.1126\/science.aaf6814","volume":"354","author":"FE Dewey","year":"2016","unstructured":"Dewey, F. E. et al. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science 354, aaf6814 (2016).","journal-title":"Science"},{"key":"416_CR135","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41436-018-0308-x","volume":"21","author":"MR Hart","year":"2019","unstructured":"Hart, M. R. et al. Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. Genet. Med. 21, 1100\u20131110 (2019).","journal-title":"Genet. Med."},{"key":"416_CR136","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/gim.2013.153","volume":"16","author":"L Shahmirzadi","year":"2014","unstructured":"Shahmirzadi, L. et al. Patient decisions for disclosure of secondary findings among the first 200 individuals undergoing clinical diagnostic exome sequencing. Genet. Med. 16, 395\u2013399 (2014).","journal-title":"Genet. Med."},{"key":"416_CR137","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/cts.12493","volume":"11","author":"JK Hicks","year":"2018","unstructured":"Hicks, J. K. et al. Patient decisions to receive secondary pharmacogenomic findings and development of a multidisciplinary practice model to integrate results into patient care. Clin. Transl Sci. 11, 71\u201376 (2018).","journal-title":"Clin. Transl Sci."},{"key":"416_CR138","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cge.12167","volume":"84","author":"S Daack-Hirsch","year":"2013","unstructured":"Daack-Hirsch, S. et al. \u2018Information is information\u2019: a public perspective on incidental findings in clinical and research genome-based testing. Clin. Genet. 84, 11\u201318 (2013).","journal-title":"Clin. Genet."},{"key":"416_CR139","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1086\/302374","volume":"64","author":"EW Almqvist","year":"1999","unstructured":"Almqvist, E. W., Bloch, M., Brinkman, R., Craufurd, D. & Hayden, M. R. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am. J. Hum. Genet. 64, 1293\u20131304 (1999).","journal-title":"Am. J. Hum. Genet."},{"key":"416_CR140","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/ejhg.2014.42","volume":"22","author":"J Owen","year":"2014","unstructured":"Owen, J. et al. Predictive testing for inherited prion disease: report of 22 years experience. Eur. J. Hum. Genet. 22, 1351\u20131356 (2014).","journal-title":"Eur. J. Hum. Genet."},{"key":"416_CR141","unstructured":"ABC v St George\u2019s Hospital NHS Trust. in MRS JUSTICE YIP DBE http:\/\/www.bailii.org\/ew\/cases\/EWHC\/QB\/2020\/455.html (2020). This judgement clarified the duties of the treating clinicians when a patient refuses to tell their relatives of a pertinent genetic mutation; it has brought substantial change to clinical practice."},{"key":"416_CR142","first-page":"278","volume":"661","author":"Florida Supreme Court Pate v","year":"1995","unstructured":"Florida Supreme Court Pate v. Threlkel. Wests South Report 661, 278\u2013282 (1995).","journal-title":"Wests South Report"},{"key":"416_CR143","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12687-012-0134-9","volume":"4","author":"ME Wiens","year":"2013","unstructured":"Wiens, M. E., Wilson, B. J., Honeywell, C. & Etchegary, H. A family genetic risk communication framework: guiding tool development in genetics health services. J. Community Genet. 4, 233\u2013242 (2013).","journal-title":"J. Community Genet."},{"key":"416_CR144","unstructured":"British Society for Genetic Medicine. Consent and Confidentiality in Genomic Medicine 3rd Ed. (Joint Committee on Genomics in Medicine, 2019)"},{"key":"416_CR145","unstructured":"Association of British Insurers. Genetics and Insurance. ABI https:\/\/www.abi.org.uk\/products-and-issues\/choosing-the-right-insurance\/health-insurance\/genetics-and-insurance\/ (ABI Webpage)."},{"key":"416_CR146","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170843","volume":"12","author":"H LaDuca","year":"2017","unstructured":"LaDuca, H. et al. Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels. PLoS ONE 12, e0170843 (2017).","journal-title":"PLoS ONE"},{"key":"416_CR147","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00401-019-01962-9","volume":"137","author":"C Pottier","year":"2019","unstructured":"Pottier, C. et al. Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathol. 137, 879\u2013899 (2019).","journal-title":"Acta Neuropathol."},{"key":"416_CR148","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ana.22647","volume":"71","author":"CS Ku","year":"2012","unstructured":"Ku, C. S. et al. Exome sequencing: dual role as a discovery and diagnostic tool. Ann. Neurol. 71, 5\u201314 (2012).","journal-title":"Ann. Neurol."},{"key":"416_CR149","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/jhg.2013.114","volume":"59","author":"B Rabbani","year":"2014","unstructured":"Rabbani, B., Tekin, M. & Mahdieh, N. The promise of whole-exome sequencing in medical genetics. J. Hum. Genet. 59, 5\u201315 (2014).","journal-title":"J. Hum. Genet."},{"key":"416_CR150","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jalz.2016.01.012","volume":"12","author":"R Cacace","year":"2016","unstructured":"Cacace, R., Sleegers, K. & Van Broeckhoven, C. Molecular genetics of early-onset Alzheimer\u2019s disease revisited. Alzheimers Dement. 12, 733\u2013748 (2016). This paper lays out the known mutations in APP, PSEN1 and PSEN2 and their location in relation to functional domains in great detail.","journal-title":"Alzheimers Dement."},{"key":"416_CR151","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ng1718","volume":"38","author":"A Rovelet-Lecrux","year":"2006","unstructured":"Rovelet-Lecrux, A. et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 24\u201326 (2006).","journal-title":"Nat. Genet."},{"key":"416_CR152","volume":"7","author":"A Neueder","year":"2017","unstructured":"Neueder, A. et al. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington\u2019s disease patients. Sci. Rep. 7, 1307 (2017).","journal-title":"Sci. Rep."},{"key":"416_CR153","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41582-018-0047-2","volume":"14","author":"R Balendra","year":"2018","unstructured":"Balendra, R. & Isaacs, A. M. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat. Rev. Neurol. 14, 544\u2013558 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"416_CR154","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00401-012-1017-1","volume":"124","author":"I Santa-Maria","year":"2012","unstructured":"Santa-Maria, I. et al. The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol. 124, 693\u2013704 (2012).","journal-title":"Acta Neuropathol."},{"key":"416_CR155","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00401-019-02035-7","volume":"138","author":"SL Forrest","year":"2019","unstructured":"Forrest, S. L., Kril, J. J. & Halliday, G. M. Cellular and regional vulnerability in frontotemporal tauopathies. Acta Neuropathol. 138, 705\u2013727 (2019).","journal-title":"Acta Neuropathol."},{"key":"416_CR156","doi-asserted-by":"publisher","unstructured":"Craufurd, D. & Harper, P. S. Genetic counseling and genetic testing for neurogenetic disorders. Neurogenetics https:\/\/doi.org\/10.1017\/CBO9781139087711.002 (2012).","DOI":"10.1017\/CBO9781139087711.002"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41582-020-00416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-020-00416-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41582-020-00416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:12:20Z","timestamp":1684606340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-020-00416-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":156,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1038\/s41582-020-00416-1","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"11 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}